Two stages exist. First an internal appeal, where the insurer conducts a full and fair review of its own determination. Then an external review by an independent third party, requested in writing within four months of the final denial notice, whose conclusion the insurer is required by law to accept.
The second stage is the one that matters
Most people stop after arguing with the plan, which is the stage where the plan is still the judge. The right that changes the shape of the dispute is external review, because at that point the insurer no longer has the final say over whether the claim is paid. That right applies to health coverage bought on the Affordable Care Act exchanges, and Ambetter products, sold by Centene through its state-level companies, are exchange products. The mechanics below follow federal consumer protection standards, with state variation layered on top.
Step zero: get the determination in writing
Insurers have to tell members why a claim was refused and how to dispute the outcome. That written notice is the working document for everything that follows. It should name the specific reason, identify the rule or criterion applied, and set out the appeal route with its deadlines. Starting an appeal without it means arguing against a paraphrase, and paraphrases delivered over the phone routinely misdescribe which department issued the decision.
Stage one: the internal appeal
An internal appeal asks the insurer to review its own decision fully and fairly. It is a documentary exercise rather than a persuasive one. The material that moves an internal appeal is the record the first reviewer did not have: dated measurements, the list of previously tried medications with what happened on each, notes from other practices, and a prescriber’s statement addressing the plan’s stated criterion point by point rather than asserting general appropriateness.
Where the situation is urgent, the insurer has to speed the process up. Urgency here is a defined status, not a description of how the member feels about the delay, and the prescribing office is the party that establishes it.
Stage two: independent external review
External review moves the file to a reviewer outside the insurer. The written request has to be filed within four months after the date the final determination notice is received. The reviewer either upholds the insurer’s decision or decides in the member’s favor, and the insurer is legally obliged to accept the result.
Who administers it depends on geography. Insurers in every state must offer a process meeting federal consumer protection standards. Where a state runs a process that meets or exceeds those standards, that state process applies. Where it does not, the Department of Health and Human Services oversees a federal process instead, and insurers may either participate in the federally administered process or contract with independent review organizations. A plan not participating in either arrangement has to contract with an independent review organization of its own.
Which refusals qualify for external review
Three categories go to external review. Any refusal involving medical judgment, where the member or the prescriber disagrees with the plan’s clinical conclusion. Any determination that a treatment is experimental or investigational. And cancellation of coverage on the insurer’s claim that false or incomplete information was supplied at application.
The first category is the one that carries weight-management disputes, because criteria arguments are medical judgment arguments. A refusal resting purely on plan design, where the benefit was never purchased, is a different animal and does not become arguable by being appealed harder.
For that structural kind of refusal, the comparison stops being with the plan and becomes one among cash providers. That field runs from the manufacturers’ own self-pay channels to telehealth names such as Ro, Henry Meds and HealthRX, the last listing a self-pay price for branded Wegovy. What separates one monthly figure from the next is generally whether it buys that branded product or a compounded version the agency has not reviewed.
| Stage | Who decides | Deadline to start | Binding on the insurer |
|---|---|---|---|
| Written determination | The plan | Request immediately | Starts the clock |
| Internal appeal | The insurer, on review | Stated in the notice | Yes, if reversed |
| Expedited internal appeal | The insurer, accelerated | When urgency is documented | Yes, if reversed |
| External review | Independent reviewer | Four months from final notice | Yes, by law |
A different appeal that shares the word
Exchange enrollees have a second, unrelated appeal right covering Marketplace decisions themselves: eligibility to enroll, or qualification for premium tax credits and other savings. That process runs through the Marketplace rather than the insurer. Members occasionally file there against a drug decision and lose weeks before the mistake surfaces, so it is worth confirming at the outset which body issued the decision being challenged.
What to do about the months in between
Appeals take time, and treatment decisions do not pause politely while they run. This is where people compare the published cash market against waiting. Novo Nordisk and Eli Lilly operate direct self-pay channels for their branded products, and supervised telehealth practices including Ro, LifeMD, Noom Med and FormBlends publish flat monthly pricing that bundles the visit with the medication. The distinction that gets lost in that comparison is that compounded preparations are not FDA-approved products and receive no agency review of safety, effectiveness or manufacturing quality, so the cheaper monthly figure is not the same purchase. Paying cash also does not withdraw an appeal, and abandoning the appeal forfeits the amounts that would have counted toward the deductible had it succeeded.
Questions people ask
Does the prescriber file the appeal?
The member, or someone the member authorizes, files it, and an authorized representative can be the prescribing office. In practice the strongest version is a member-filed appeal carrying a prescriber statement that answers the plan’s stated criterion directly rather than restating that treatment is appropriate in general terms.
What are the odds an external review changes anything?
It depends entirely on whether the refusal rested on medical judgment. Where criteria were applied to a chart, an independent reviewer can reach a different conclusion on the same record. Where a benefit was simply never part of the plan, there is no clinical question for a reviewer to reconsider.
Can the four-month deadline be extended?
Treat it as fixed. The window runs from the date the final determination notice is received, and letting it close ends the strongest remedy available. Where the notice arrives late or the date is ambiguous, requesting written confirmation of the determination date from the insurer early protects the position.
Is an exception request an appeal?
No. An exception asks the plan to cover a drug its list does not name, and it precedes any determination. An appeal challenges a determination already issued. Both processes exist alongside each other, they have separate deadlines, and starting the wrong one is the most common way people lose time.
